KRAS and osteosarcoma: Here, we found that treatment with the pan-RAS inhibitor daraxonrasib led to dose-dependent inhibition of growth and migration in the KRAS G12S osteosarcoma cell line HOS-143B, while having virtually no effect on KRAS wild-type osteosarcoma line HOS.